EHA2026 | What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM?

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What are the updated 4-year results from the phase III DREAMM-7 trial (NCT04246047) in relapsed/refractory multiple myeloma (RRMM)?  

Key points¹ 

• The ongoing open-label, randomized, phase III DREAMM-7 trial is evaluating the efficacy and safety of belantamab mafodotin + bortezomib + dexamethasone (BVd) vs daratumumab + bortezomib + dexamethasone (DVd) in patients with RRMM who have received ≥1 prior line of therapy (LoT). 
• After >4 years of follow-up (median, 52.9 months), PFS benefit was maintained in the intention-to-treat (ITT) population (BVd, n = 243; DVd, n = 251). 
• In the ITT population, median OS was not reached (NR; 95% confidence interval [CI], 63.0 months–NR) in the BVd arm vs 58.3 months (95% CI, 41.4 months–NR) in the DVd arm (hazard ratio [HR], 0.62; 95% CI, 0.46–0.82). 
• A total of 38% of patients had a stringent complete response (sCR) or CR with BVd vs 21% with DVd.  
• At the 4-year landmark, OS rates in the BVd arm were 98% in patients with sCR and 82% in those with CR, indicating sustained OS.  
• Median PFS in the BVd arm was NR in patients with sCR or CR and 56.2 months and 45.0 months, respectively, in similar responding patients treated with DVd.  
• No new safety concerns were observed. 
• The incidence of adverse events (AEs) remained consistent with previous analyses, with no new fatal AEs observed, and infection rates were unchanged. 
• Health-related quality of life (HRQoL) remained stable over time, suggesting long-term tolerability of belantamab mafodotin. 
• These findings further support BVd as a treatment option for patients with RRMM at first relapse or later. 

This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.